Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Association Between Preoperative Magnetic Resonance Imaging–based Urethral Parameters and Continence Recovery Following Robot-assisted Radical Prostatectomy
Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
Are we improving functional outcomes of prostate cancer patients treated with robot-assisted radical prostatectomy? A 10-year analysis in men treated at two high volume, tertiary referral centers
Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis
Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for treatment selection